UNRAVELING THE MULTIFACETED LANDSCAPE OF ULCERATIVE COLITIS: A CONTEMPORARY CLINICAL PERSPECTIVE AND   TREATMENT WITH ASKOLIT

Ibragim  R. Askarov; Khabibullo N. Kodirov

Authors

Ibragim R. Askarov Andijan State University Professor of the Department of Chemistry, Doctor of Chemistry, Honored Inventor of Uzbekistan, Chairman of the TABOBAT Academy of Uzbekistan
Khabibullo N. Kodirov Andijan State Medical Institute Assistant of the Department of Propaedeutics of Internal Medicine

Keywords:

Personalized medicine., Immunomodulators, AskolitA, Diagnosis

Abstract

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), presents a significant clinical challenge. This article provides a contemporary clinical perspective, synthesizing current understanding of its pathogenesis, diagnostic modalities, and therapeutic strategies. We explore the complex interplay of genetic predisposition, environmental triggers, and immunological dysregulation that characterizes UC. Furthermore, we discuss the evolving landscape of treatment options, including conventional therapies and novel biologic agents, emphasizing personalized management based on disease severity and patient-specific factors.

Keywords:Ulcerative colitis, AskolitA, biologically active substitute. Inflammatory bowel disease, Pathogenesis, Diagnosis, Treatment, Biologics, Endoscopy, Immunomodulators, Personalized medicine.

References

Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462-2476. (A pivotal study demonstrating the efficacy of infliximab in UC.)

Sands BE, Feagan BG, van Assche G, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-712. (Key trial for the integrin inhibitor vedolizumab in UC.)

Sandborn WJ, Ghosh S, Panaccione R, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;377(11):1041-1050. (Landmark trial for the JAK inhibitor tofacitinib in UC.)

Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Part 1: Definitions and diagnosis. J Crohns Colitis. 2012;6(1):5-19. (Focuses on the diagnostic aspects of UC.)

Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Part 2: Current management. J Crohns Colitis. 2012;6(10):991-1030. (Focuses on the treatment strategies for UC.)

Roda G, Jovani M, Torres J, et al. Fecal calprotectin in ulcerative colitis: a systematic review and meta-analysis. Inflamm Bowel Dis. 2017;23(12):2083-2092. (A comprehensive review on the role of fecal calprotectin in UC.)